TrialDiabetes care2018

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.

Andrew J Ahmann et al.PubMed ↗Publisher ↗

No numbers read from the abstract.